Sibling Capital, LLC Participates in Relypsa’s $80 Million Private Financing Transaction

Funds will Support the Advancement of Patiromer (RLY5016) through Phase 3 and NDA Submission

RANCHO SANTA FE, Calif.--()--Sibling Capital, LLC today announced its formation, which is focused on investment specific opportunities from of a variety of high net-worth individual investors from around the world. Sibling plans on making targeted investments in up to six opportunities through individual funds focusing on the juncture of chemistry, medicine and material sciences. Sibling takes a unique personal approach in allowing their high net-worth individuals access to venture capital financing as an asset class, as well as allowing its investors to closely monitor the progress of their investments. Dr. Coufal, President of Sibling Capital, stated, “I’m excited to proceed with a new opportunity as we differentiate Sibling from other venture capital models in order to provide a bridge between company building and private investing.”

“In evaluating investment opportunities, it became apparent to me that I had to diversify our portfolio into a venture capital strategy which could provide a sound return in an otherwise stagnant and volatile economy. Sibling Capital presented a sophisticated and convincing option with its first financing opportunity,” stated Jim Givan, investor in Sibling Capital.

Sibling today also announced its participation in its first financing through its first fund, Sibling Capital Fund I. This first investment marks Sibling’s entrance into the life sciences sector with its participation in the $80 million Series C preferred stock financing in Relypsa, Inc., alongside industry leading funds including OrbiMed Advisors, 5AM Ventures, New Leaf Venture Partners, Sprout Group, Delphi Ventures and Mediphase Venture Partners. The proceeds will be used by Relypsa to fund late-stage development, submission of a new drug application (NDA) and commercial planning for patiromer (RLY5016), Relypsa’s high capacity non-absorbed oral potassium binder being developed for the treatment of hyperkalemia.

“I have worked with Dr. Coufal as a key contributor on our scientific and medical advisory board for many years enabling the successes of Ilypsa (purchased by Amgen in 2007) and Relypsa. I am excited for her to now lend her expertise to Relypsa and other companies through the formation of Sibling Capital,” stated Gerrit Klaerner, Ph.D., President of Relypsa.

About Sibling Capital, LLC

Sibling Capital, LLC is a family-oriented private equity firm that combines proven industry knowledge and financial expertise in evaluating investment opportunities. Our strategy is to leverage long-standing relationships to identify investment opportunities with companies seeking late-stage or growth-oriented capital across a variety of industries. For more information visit www.siblingcapital.com.

Contacts

Sibling Capital, LLC is still open to new investors, for more information, please contact:
Brian Isern, 504-715-8335
Co-Founder, Vice-President
bisern@siblingcapital.com

Release Summary

Sibling Capital enters the life sciences sector with its participation in the $80 million Series C preferred stock financing in Relypsa, Inc., through Sibling Capital Fund I for patiromer development.

Contacts

Sibling Capital, LLC is still open to new investors, for more information, please contact:
Brian Isern, 504-715-8335
Co-Founder, Vice-President
bisern@siblingcapital.com